Loews

L

時価総額 $226億

NEW YORK, Oct. 13, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) will report third quarter 2026 financial results on Monday, November 2, 2026. On that date the Company will also post earnings remarks on its website.

Ginkgo Bioworks and Eli Lilly announced a partnership last month focused on AI drug discovery. The stock has skyrocketed since the partnership was announced.

NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) announced today the declaration of the Company's quarterly dividend of $0.0625 per share of Common Stock, payable September 1, 2026 to shareholders of record as of the close of business on August 19, 2026. Loews Corporation is a diversified company with businesses in the insurance, energy, hospitality, and packaging industries.

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) today released its second quarter 2026 financial results. Second Quarter 2026 highlights: Loews Corporation reported net income of $444 million, or $2.16 per share, in the second quarter of 2026, compared to $391 million, or $1.87 per share, in the second quarter of 2025.

NEW YORK, July 14, 2026 /PRNewswire/ -- Loews Corporation (NYSE: L) will report second quarter 2026 financial results on Monday, August 3, 2026. On that date the Company will also post earnings remarks on its website.

As EQB prepares to close its Acquisition of PC Financial on July 1, 2026, the company announces a strengthened leadership team drawing on talent from both organizations, positioning EQB for a differentiated phase of growth Key appointments include: Ian Hanning from PC Financial to SVP, Credit Cards and Loyalty Mark Snyder from PC Financial to SVP, Credit Risk and Data Analytics Michaela Garfield from PC Financial to SVP, Customer Growth, Experience and Strategy, Personal Banking Puneesh Arora from PC Financial to EVP and Chief Risk Officer, with current EVP and Chief Risk Officer Marlene Lenarduzzi to act as Special Advisor until Jan 1, 2027 Daniel Rethazy's mandate expanding as EVP Personal Banking to include PC Financial businesses Anilisa Sainani's mandate as CFO expanding to include Strategy and Corporate Development Gavin Stanley's mandate as CHRO expanding to include Brand and Marketing Caleb Rubin appointed as Chief Brand Officer Dan Broten appointed Chief Digital Officer David Wilkes appointed SVP, Deposits, Payments and Small Business Banking Dipti Patel elevated to Chief Credit Officer and Deputy CRO Julia Davidson appointed Chief Operating Officer, Commercial Banking Lemar Persaud appointed SVP, Investor Relations and Enterprise Performance Management TORONTO, June 16, 2026 /PRNewswire/ - EQB Inc. (TSX: EQB) today announced a comprehensive set of executive appointments and elevations as the company prepares to close its acquisition ("the Acquisition") of PC Financial1 from Loblaw Companies Limited ("Loblaw") (TSX: L) on July 1, 2026. This strengthened leadership team brings multiple senior PC Financial leaders onto the EQB Executive Leadership Team (ELT), alongside a series of expanded mandates for existing leaders, building the organizational capabilities required to serve millions of Canadians across a broader and more complex set of financial products and services.

Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway Transformative partnership between Tsuut'ina Nation, Taza Development Corp. and Real Canadian Superstore advances as opening preparations get underway

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- In the latest edition of its Food Inflation Report, Loblaw is pleased to provide context around what's impacting food prices – now and into the future. This report follows Statistics Canada's release of data for the month of April.

TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Ahead of Menstrual Health Day on May 28, Shoppers Foundation for Women's Health™ is proud to announce $300,000 in funding commitments over two years to support organizations advancing menstrual equity in Canada.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for met.